Cereno Scientific move to request “compassionate use” of CS1 for treatment of patients with rare disease PAH
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the company will submit a request for expanded access to investigational drug CS1 for use as a treatment outside of a clinical trial, sometimes called “compassionate use.” The initiative is prompted by a request from an investigator in the ongoing Phase II study of CS1. Cereno will submit a request to the FDA under the ‘Expanded Access to Investigational Drugs for Treatment Use’ requesting expanded access to CS1 which initially will be